Safrazine

DB09253ApprovedWithdrawnSmall molecule

Safrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.

Mechanism: Pharmacologically active on Monoamine oxidase
Curator reviewed
Primary indication: For the treatment of depression.Curator reviewed
Formula / weight: C₁₁H₁₆N₂O₂ · 208.261 g/mol (avg)
Also known as: Safra

Resolves to

Compound

UNIIF5G0P5378CCAS33419-68-0ChEMBLCHEMBL3301845PubChem34042

Structure

InChIKeyIBWPUTAKVGZXRB-UHFFFAOYSA-NSMILESCC(CCC1=CC2=C(OCO2)C=C1)NN

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,334Drug interactionsStructured to mechanism, not free text

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Safrazine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account